Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkae432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Andrew J Fratoni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Tobramycin, Meropenem, Anti-Bacterial Agents, Neutropenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Antimicrobial Resistance Innovation Fund, UK Department of Health and Social Care, Administration for Strategic Preparedness and Response.
Abstract (Originalsprache)
Background
Murine pneumonia models play a fundamental role in the preclinical development of novel compounds seeking an indication for the treatment of pneumonia. It is vital that plasma exposures in these models are not used as a surrogate for exposure in pulmonary epithelial lining fluid (ELF). Herein, human-simulated regimens (HSRs) in both plasma and ELF of meropenem, cefiderocol and tobramycin are described in the standardized COMBINE murine neutropenic pneumonia model. Materials and methods HSRs were developed in both plasma and ELF for meropenem and cefiderocol as 2 g q8h 3 h infusions, and tobramycin 7 mg/kg 30 min infusion. Pharmacokinetic studies were performed to confirm plasma and ELF exposures in mice that recapitulated %fT > MIC for meropenem and cefiderocol, and fCmax and fAUC0-24 for tobramycin in humans.
Results
Concentration–time profiles and relevant pharmacodynamic exposures for all three compounds were well matched in mice relative to humans. None of the plasma HSRs were able to appropriately humanize the ELF. Thus, modifications of the plasma HSRs were necessary to provide unique HSRs specific to ELF exposure for each compound.
Conclusions
It should not be assumed that lung penetration in mice relative to humans is equivalent. With HSRs confirmed for these three drugs with established clinical use in the treatment of patients with pneumonia, these humanized exposures within the standardized model will allow for back-translation of anticipated efficacy and provide purposeful quantitative benchmarks for cfu/lung assessments for researchers on an international scale.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
- CARB-X, Boston, MA, USA.
ORCID-Profile: David P Nicolau
Förderung
- Global Antimicrobial Resistance Innovation Fund
- UK Department of Health and Social Care
- Administration for Strategic Preparedness and Response
- US Department of Health and Human Services
- Wellcome
- NIH HHS
- Wellcome Trust
- NIEHS NIH HHS
Zitieren
APA
Fratoni, A. J., Padgett, A. M., Roenfanz, H. F., Duffy, E. M., & Nicolau, D. P. (2025). Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae432
Vancouver
Fratoni AJ, Padgett AM, Roenfanz HF, Duffy EM, Nicolau DP. Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae432
BibTeX
@article{Fratoni2025,
author = {Fratoni, Andrew J and Padgett, Alissa M and Roenfanz, Hanna F and Duffy, Erin M and Nicolau, David P},
title = {Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkae432}
}
EUVIMED